BRPI1016150A2 - compostos heterocíclicos e seus usos. - Google Patents
compostos heterocíclicos e seus usos.Info
- Publication number
- BRPI1016150A2 BRPI1016150A2 BRPI1016150A BRPI1016150A BRPI1016150A2 BR PI1016150 A2 BRPI1016150 A2 BR PI1016150A2 BR PI1016150 A BRPI1016150 A BR PI1016150A BR PI1016150 A BRPI1016150 A BR PI1016150A BR PI1016150 A2 BRPI1016150 A2 BR PI1016150A2
- Authority
- BR
- Brazil
- Prior art keywords
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22048809P | 2009-06-25 | 2009-06-25 | |
| PCT/US2010/039942 WO2010151740A2 (en) | 2009-06-25 | 2010-06-25 | Heterocyclic compounds and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1016150A2 true BRPI1016150A2 (pt) | 2016-04-19 |
Family
ID=43066540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016150A BRPI1016150A2 (pt) | 2009-06-25 | 2010-06-25 | compostos heterocíclicos e seus usos. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20100331306A1 (pt) |
| EP (1) | EP2445900B1 (pt) |
| JP (1) | JP2013527123A (pt) |
| KR (1) | KR20140068742A (pt) |
| AR (1) | AR077267A1 (pt) |
| AU (1) | AU2010265974B2 (pt) |
| BR (1) | BRPI1016150A2 (pt) |
| CA (1) | CA2781865A1 (pt) |
| CL (1) | CL2011003296A1 (pt) |
| EA (1) | EA201270013A1 (pt) |
| IL (1) | IL216885A0 (pt) |
| MX (1) | MX2011013510A (pt) |
| SG (1) | SG176986A1 (pt) |
| TW (1) | TW201111362A (pt) |
| UY (1) | UY32743A (pt) |
| WO (1) | WO2010151740A2 (pt) |
| ZA (1) | ZA201200611B (pt) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2139882B1 (en) | 2007-03-23 | 2013-12-25 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| DK2137186T3 (en) | 2007-03-23 | 2016-04-18 | Amgen Inc | Heterocyclic compounds and their uses |
| CA2725014C (en) | 2008-05-30 | 2014-06-17 | Amgen Inc. | Inhibitors of pi3 kinase |
| SG176986A1 (en) | 2009-06-25 | 2012-02-28 | Amgen Inc | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
| CA2765817A1 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors |
| KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Ｐｉ3ｋ 저해물질로서의 피리미디논 |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| MX2012006953A (es) | 2009-12-18 | 2012-10-09 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| MX2012015143A (es) * | 2010-06-30 | 2013-07-03 | Amgen Inc | Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta. |
| US20130085131A1 (en) * | 2010-07-01 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds and their uses |
| MX2013005567A (es) * | 2010-11-17 | 2013-10-30 | Amgen Inc | Derivados de quinolina como inhibidores de pik3. |
| EP3660016A1 (en) | 2010-12-20 | 2020-06-03 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| MX2013007261A (es) * | 2010-12-23 | 2013-11-04 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| CN102070520A (zh) * | 2011-01-14 | 2011-05-25 | 华东师范大学 | 以3-氧代-2,3-二芳基丙醛制备3-芳基取代喹啉的方法 |
| WO2012100732A1 (en) * | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| TWI572599B (zh) | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| PH12013502240B1 (en) | 2011-05-04 | 2018-06-27 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinase |
| MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| PT3513793T (pt) | 2011-09-02 | 2021-05-10 | Incyte Holdings Corp | Heterociclilaminas como inibidores de pi3k |
| US9056817B2 (en) * | 2011-09-12 | 2015-06-16 | Council Of Scientific And Industrial Research | Arylated β-dicarbonyl compounds and process for the preparation thereof |
| US9376425B2 (en) | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| EP2790705B1 (en) | 2011-12-15 | 2017-12-06 | Novartis AG | Use of inhibitors of the activity or function of pi3k |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| ME02473B (me) * | 2012-04-04 | 2017-02-20 | Amgen Inc | Heterociklična jedinjenja i njihova primjena |
| TW201414734A (zh) | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
| CN104884448A (zh) | 2012-10-16 | 2015-09-02 | 詹森药业有限公司 | Rorγt的杂芳基连接的喹啉基调节剂 |
| CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
| US9290476B2 (en) | 2012-10-16 | 2016-03-22 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| JP6207100B2 (ja) | 2012-12-21 | 2017-10-04 | ギリアード カリストガ エルエルシー | イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤 |
| AU2013364068B2 (en) | 2012-12-21 | 2016-10-20 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| WO2014130470A1 (en) | 2013-02-19 | 2014-08-28 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
| MX374513B (es) | 2013-03-14 | 2025-03-06 | Amgen Inc | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| PL3008053T3 (pl) | 2013-06-14 | 2018-08-31 | Gilead Calistoga Llc | Inhibitory 3-kinazy fosfatydyloinozytolu |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| JP6320523B2 (ja) | 2013-10-15 | 2018-05-09 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγＴの第二級アルコールキノリニルモジュレータ |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| BR112016008258A2 (pt) | 2013-10-15 | 2017-10-10 | Janssen Pharmaceutica Nv | moduladores de ror?t de quinolinila |
| BR112016008215A2 (pt) | 2013-10-15 | 2017-09-26 | Janssen Pharmaceutica Nv | moduladores de quinolinila ligados por alquila de roryt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| BR112016010564A2 (pt) | 2013-11-11 | 2017-10-10 | Amgen Inc | terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres |
| WO2015106014A1 (en) | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
| WO2015106012A1 (en) | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| HK1232227A1 (zh) | 2014-07-04 | 2018-01-05 | Lupin Limited | 作为pi3k抑制剂的喹嗪酮衍生物 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG10201907576SA (en) | 2015-02-27 | 2019-09-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| CN106008479B (zh) * | 2015-03-06 | 2020-01-10 | 南京圣和药业股份有限公司 | 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用 |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| KR101845931B1 (ko) | 2015-06-18 | 2018-04-05 | 한국화학연구원 | 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| EP3400227B1 (en) | 2016-03-05 | 2021-03-31 | Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6975184B2 (ja) | 2016-07-04 | 2021-12-01 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | ベンゾスルタム類及び類似体、並びに、殺菌剤としてのそれらの使用 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| KR20200041358A (ko) | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| SG11202011680YA (en) | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| AU2019327555B2 (en) | 2018-08-31 | 2025-01-16 | Amgen, Inc. | Processes for preparing a MDM2 inhibitor |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| WO2020236947A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| US20240139193A1 (en) | 2019-10-15 | 2024-05-02 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
| CN115968369B (zh) | 2020-06-30 | 2026-04-28 | 株式会社保宁 | 作为pi3k抑制剂的化合物的制备方法及用于制备其的中间体化合物 |
| PT4426434T (pt) | 2021-11-02 | 2025-11-24 | Flare Therapeutics Inc | Agonistas inversos de pparg e suas utilizações |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| DE3020458C2 (de) | 1980-05-29 | 1986-07-31 | Herzog, Thomas, Prof. Dr., 3500 Kassel | Vorgehängte Fassaden-, Bau- oder Dekorationsplatte |
| TW232013B (pt) | 1992-04-24 | 1994-10-11 | Takeda Pharm Industry Co Ltd | |
| NO940245D0 (no) | 1993-01-28 | 1994-01-24 | Takeda Chemical Industries Ltd | Quinolin eller quinazolinderivater, deres fremstilling og anvendelse |
| EP0749426A1 (en) | 1994-03-08 | 1996-12-27 | Takeda Chemical Industries, Ltd. | Quinoline or quinazoline derivatives as anti-inflammatory agents, in particular for treating arthritis |
| US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
| GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| US5822910A (en) | 1997-10-02 | 1998-10-20 | Shewmake; I. W. | Fishing line tensioning device |
| WO1999047485A1 (en) * | 1998-03-18 | 1999-09-23 | Humanetics Corporation | Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents |
| US6355636B1 (en) * | 1999-04-21 | 2002-03-12 | American Cyanamid Company | Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
| EP2139882B1 (en) * | 2007-03-23 | 2013-12-25 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| DK2137186T3 (en) * | 2007-03-23 | 2016-04-18 | Amgen Inc | Heterocyclic compounds and their uses |
| US8367702B2 (en) | 2007-09-26 | 2013-02-05 | Astellas Pharma Inc. | Quinolone derivative |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| US20100125091A1 (en) | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds as ion channel modulators |
| GB0821693D0 (en) * | 2008-11-27 | 2008-12-31 | Ucb Pharma Sa | Therapeutic agents |
| EP2396315B1 (en) | 2009-02-13 | 2016-08-31 | UCB Biopharma SPRL | Quinoline derivatives as pi3k kinase inhibitors |
| SG176986A1 (en) | 2009-06-25 | 2012-02-28 | Amgen Inc | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
| EP2499126B1 (en) | 2009-11-12 | 2015-01-07 | UCB Pharma, S.A. | Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors |
| MX2012006953A (es) * | 2009-12-18 | 2012-10-09 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| US20130085131A1 (en) * | 2010-07-01 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds and their uses |
-
2010
- 2010-06-25 SG SG2011096039A patent/SG176986A1/en unknown
- 2010-06-25 EP EP10731874.3A patent/EP2445900B1/en active Active
- 2010-06-25 MX MX2011013510A patent/MX2011013510A/es not_active Application Discontinuation
- 2010-06-25 BR BRPI1016150A patent/BRPI1016150A2/pt not_active IP Right Cessation
- 2010-06-25 EA EA201270013A patent/EA201270013A1/ru unknown
- 2010-06-25 WO PCT/US2010/039942 patent/WO2010151740A2/en not_active Ceased
- 2010-06-25 TW TW099121049A patent/TW201111362A/zh unknown
- 2010-06-25 AR ARP100102285A patent/AR077267A1/es not_active Application Discontinuation
- 2010-06-25 US US12/823,449 patent/US20100331306A1/en not_active Abandoned
- 2010-06-25 CA CA2781865A patent/CA2781865A1/en not_active Abandoned
- 2010-06-25 UY UY0001032743A patent/UY32743A/es not_active Application Discontinuation
- 2010-06-25 AU AU2010265974A patent/AU2010265974B2/en not_active Expired - Fee Related
- 2010-07-27 JP JP2012517761A patent/JP2013527123A/ja active Pending
- 2010-07-27 KR KR1020127001780A patent/KR20140068742A/ko not_active Withdrawn
-
2011
- 2011-12-08 IL IL216885A patent/IL216885A0/en unknown
- 2011-12-23 CL CL2011003296A patent/CL2011003296A1/es unknown
-
2012
- 2012-01-25 ZA ZA2012/00611A patent/ZA201200611B/en unknown
-
2016
- 2016-07-26 US US15/219,624 patent/US9873704B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010265974B2 (en) | 2014-09-11 |
| TW201111362A (en) | 2011-04-01 |
| US20100331306A1 (en) | 2010-12-30 |
| EA201270013A1 (ru) | 2012-06-29 |
| SG176986A1 (en) | 2012-02-28 |
| CA2781865A1 (en) | 2010-12-29 |
| WO2010151740A3 (en) | 2011-03-31 |
| EP2445900A2 (en) | 2012-05-02 |
| US20160333017A1 (en) | 2016-11-17 |
| US9873704B2 (en) | 2018-01-23 |
| UY32743A (es) | 2010-12-31 |
| AR077267A1 (es) | 2011-08-17 |
| KR20140068742A (ko) | 2014-06-09 |
| JP2013527123A (ja) | 2013-06-27 |
| WO2010151740A4 (en) | 2011-05-19 |
| IL216885A0 (en) | 2012-03-01 |
| WO2010151740A2 (en) | 2010-12-29 |
| MX2011013510A (es) | 2012-03-07 |
| EP2445900B1 (en) | 2016-03-02 |
| AU2010265974A1 (en) | 2012-01-19 |
| CL2011003296A1 (es) | 2012-06-08 |
| ZA201200611B (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1016150A2 (pt) | compostos heterocíclicos e seus usos. | |
| BR112012000660A2 (pt) | compostos heterociclos e seus usos | |
| BRPI0817881A2 (pt) | Compostos orgânicos e seus usos | |
| HRP20190016T1 (hr) | Heterociklički spojevi i njihova upotreba | |
| BR112012002114A2 (pt) | cevadas e seu usos. | |
| BRPI0921862A2 (pt) | inibidores de raf e seus usos | |
| BR112013006272A2 (pt) | compostos de piridina e seus usos | |
| BRPI0910746A2 (pt) | reticuladores e seus usos | |
| BRPI0908853A2 (pt) | composto oligopeptídicos e seus usos | |
| BRPI1010881A2 (pt) | derivados de triazina e suas aplicações terapêuticas. | |
| BRPI1010882A2 (pt) | derivados de triazina e suas aplicações terapêuticas. | |
| BRPI0909185A2 (pt) | Derivado de vitamina e e seus usos | |
| BRPI0816075A2 (pt) | 2-(fenil substituído)-6-amino-5-alcóxi, tioalcóxi e aminoalquil-4-pirimidinacarboxilatos e seus usos como herbicidas | |
| EP2346734A4 (en) | ACTIVE WINGLET | |
| BRPI0718182A2 (pt) | Oligorribonucleotídeos e seus usos. | |
| BRPI1011801A2 (pt) | membranas biométricas e seus usos. | |
| BRPI0908906A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| PT2473528E (pt) | Formulações estáveis de polipéptidos e seus usos | |
| BRPI1016117A2 (pt) | derivados de isoxazol-isoxazol e isoxasol-isotiazol. | |
| BR112012000763A2 (pt) | derivados de piridin-4-ila | |
| EP2520259A4 (en) | DIAPER | |
| BRPI1011527A2 (pt) | derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas. | |
| BRPI1010239A2 (pt) | endoglucanases aprimoradas, derivados e seus usos | |
| EP2486905A4 (en) | HIGH-DRAWN VOIDABLE ARTICLE | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |